Kanabo Group PLC Support for New Campaign

TIDMKNB

Kanabo Group PLC

04 June 2021

4 June 2021

Kanabo Group Plc

("Kanabo" or "the Company")

Kanabo supports the "I am Billy" Campaign and Foundation to promote wider NHS patient access to Medical Cannabis in UK

Kanabo Group Plc (LSE:KNB), a medical cannabis R&D Company focused on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, is delighted to announce its support for the "I am Billy" Campaign and Foundation to promote wider NHS patient access to medical cannabis in the UK.

Highlights

-- Kanabo named as designated innovation sponsor and partner of the "I am Billy" campaign named after pioneering mother and son Charlotte and Billy Caldwell

-- Andy Morrison, non-executive director of Kanabo, appointed as trustee director of The I am Billy Foundation

-- "Walk with the Wizard" fund-raising campaign expected to arrive in Westminster on 14 June 2021

The I am Billy Campaign ( https://www.iambilly.uk/our-campaign )

I am Billy is a campaign brought forward by Billy and Charlotte Caldwell, the mother and son who changed the UK medical cannabis law in 2018. Billy Caldwell went on to pick up the first cannabis medicine prescription funded by the NHS.

I am Billy is a pioneering medical cannabis campaign which seeks to promote urgent and achievable solutions. Amongst these suggested solutions is a proposal to carry out real world, evidence-based studies at an I am Billy not-for-profit clinic. The studies will combine data and academic research into the safety and efficacy of cannabis-based medicines.

The campaign takes a positive and collaborative approach. It presents potential solutions to 'unlock the deadlock' between vulnerable and chronically ill patients and current prescription practices in the UK and Channel Islands. It aims to address the need for safe and consistent prescribing to ensure patients receive the medicine they require via NHS funding and to provide reassurance and confidence amongst NHS doctors to prescribe cannabis medicines.

I am Billy is focused on the urgent needs and real experiences of patients, but most importantly is focused on action to make a real difference. The campaign focuses on the medicalisation and legitimisation of cannabis as a medicine, along with the innovations that are advancing the sector.

Kanabo is delighted to be named as the designated innovation sponsor and partner of the I am Billy Campaign.

The I am Billy Foundation ( https://www.iambilly.uk/i-am-billy-foundation )

The foundation is a non-for-profit company that has as its aims;

-- the relief of sickness through the provision of financial assistance to those in need to meet the cost of cannabis based medicinal products (CBMPs) prescribed by a named consultant on the GMC specialist register and in accordance with clinical practice recommendations; and

   --    the advancement of education of the public in relation to the medicinal benefits of CBMPs, 

Andy Morrison, non-executive director of Kanabo was appointed as volunteer director and trustee of the I am Billy Foundation with effect from 29 March 2021.

Walk with the Wizard ( https://www.iambilly.uk/walk-with-the-wizard )

On the 28 May 2021, Billy, Charlotte and some friends set off on a 1000 mile walk from their home in Northern Ireland to Westminster via the Channel Islands. The 'Walk with the Wizard' aims to raise much-needed funds for the I am Billy Foundation to provide financial assistance to vulnerable and chronically ill NHS patients who cannot afford cannabis medicines.

The walk is expected to arrive in Westminster on or around 14 June 2021 and end at a round-table meeting with government officials to present the I am Billy solutions.

By its support of the campaign, Kanabo aims to highlight innovative products that exist on the market and which offer a solution to concerns of the medical establishment. The Company intends t o make medical cannabis formulations in the UK available in combination with its unique medical device, the VapePod, featuring consistent metred dosing. Kanabo intends to introduce the first solution of inhaling cannabis in a safe and precise way, replacing the common method of smoking medical cannabis flowers.

Avihu Tamir, CEO of Kanabo commented : "We are delighted to support Billy and Charlotte in their inspirational efforts to draw attention to and resolve the difficulties experienced by patients in accessing much-needed cannabis medicines. We believe that our VapePod medical device which provides measured dosing of medicines via inhalation will help give patients the instant relief they need while giving doctors the confidence to prescribe."

Charlotte Caldwell, founder of the I am Billy Campaign and Foundation added : "Billy and I are thrilled to have Kanabo as a leading industry partner in the campaign and to benefit from Andy's wealth of experience in the Foundation. Together, we aim to raise awareness and bring relief to thousands of patients who could benefit from medical cannabis."

For further information, please visit http://www.kanabogroup.com/ or contact the following:

Kanabo Group Plc

Tel: +(972)52-3173-633

[e-mail]

Meirav Horn

Peterhouse Capital Limited (Financial Adviser)

Tel: [phone]

Eran Zucker / Guy Miller / Allie Feuerlein

Peterhouse Capital Limited (Corporate Broker)

Lucy Williams / Charles Goodfellow

About Kanabo

Kanabo aims to be an industry leader in product development and commercialisation of both cannabis-derived products for medical patients and THC-free products for CBD consumers. The company develops high-quality medical cannabis extract formulas, medical device vaporisers, and other innovative delivery methods. Validation activities are conducted at Kanabo's research lab at the Weizmann Science Park in Israel. With a primary focus on the German and UK Markets, Kanabo has already begun penetrating the European Market, and is positioned to scale up to meet growing market demand and projected sales. Currently, Kanabo is selling its line of CBD formulas for inhalation in the UK and Germany and has agreements with distributors in the pharmaceutical and OTC sectors already in place.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFJMRTMTAMBMB

(END) Dow Jones Newswires

June 04, 2021 02:00 ET (06:00 GMT)